New targets for treatment of diabetic nephropathy: what we have learned from animal models.
about
Renal dopaminergic system: Pathophysiological implications and clinical perspectivesOmics databases on kidney disease: where they can be found and how to benefit from themAn Update on the Use of Animal Models in Diabetic Nephropathy ResearchA novel mouse model of advanced diabetic kidney disease.Renoprotective, anti-oxidative and anti-apoptotic effects of oral low-dose quercetin in the C57BL/6J model of diabetic nephropathy.BAMBI elimination enhances alternative TGF-β signaling and glomerular dysfunction in diabetic miceTwenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.Inhibition of mTOR activity in diabetes mellitus reduces proteinuria but not renal accumulation of hyaluronanFetal growth restriction promotes physical inactivity and obesity in female mice.Antihyperglycemic action of rhodiola-aqeous extract in type1-like diabetic rats.Renal improvement by zinc in diabetic mice is associated with glucose metabolism signaling mediated by metallothionein and Akt, but not Akt2.Diabetic nephropathy--emerging epigenetic mechanisms.JAK inhibition and progressive kidney disease.Advanced glycation end products induce the apoptosis of and inflammation in mouse podocytes through CXCL9-mediated JAK2/STAT3 pathway activation.High resolution molecular and histological analysis of renal disease progression in ZSF1 fa/faCP rats, a model of type 2 diabetic nephropathy.Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice.
P2860
Q22241156-50FAF374-0FBF-4F4F-A42F-AD314D736453Q24658628-C6A9E829-B67E-4E05-AD18-BA4CAAAF42F9Q26774178-6C9C5E44-3E1A-4829-85C5-440098C03336Q34712527-835F02CC-7988-4F25-999B-9864178D5A36Q34738579-44A8F026-3733-4974-AD2E-A0C08002C140Q35630822-3CBE9703-D13F-44D5-9CAD-68ACF814F909Q36297539-101A539B-FF43-4227-BB88-13648C06B936Q36754250-4CAC5763-2EE4-44BE-B08C-864EA9881F08Q37413501-03F77D9D-99C0-45AE-A13B-045CD8B00134Q37501307-BBBC1B7A-F5C2-4246-A4C3-BFE02150FF3BQ37620749-702F5F88-7DDE-4F48-87B8-DDA22058C4E8Q38227252-668F8484-D428-49C7-878C-E5E975649F98Q38270332-96CF0067-FC8D-4E76-92F2-11C2A4ED4FE6Q38604519-0E819EB6-AAB1-43EB-8C4B-950BB22D81CAQ41137803-2956B37B-B2ED-4229-810F-1FFC84B924CDQ53489601-BA45782E-DA24-4CA9-920F-6407A81B90A2
P2860
New targets for treatment of diabetic nephropathy: what we have learned from animal models.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
New targets for treatment of d ...... ve learned from animal models.
@ast
New targets for treatment of d ...... ve learned from animal models.
@en
New targets for treatment of d ...... ve learned from animal models.
@nl
type
label
New targets for treatment of d ...... ve learned from animal models.
@ast
New targets for treatment of d ...... ve learned from animal models.
@en
New targets for treatment of d ...... ve learned from animal models.
@nl
prefLabel
New targets for treatment of d ...... ve learned from animal models.
@ast
New targets for treatment of d ...... ve learned from animal models.
@en
New targets for treatment of d ...... ve learned from animal models.
@nl
P2860
P1476
New targets for treatment of d ...... ve learned from animal models.
@en
P2093
Charles E Alpers
Frank C Brosius
P2860
P356
10.1097/MNH.0B013E32835B3766
P577
2013-01-01T00:00:00Z